E

Eisai

Pharmaceutical company focused on dementia and oncology

Regional Thought Leader Liaison - Alzheimer's Disease

Full-TimeUpdated on 10/23/2026
$185k - $242.8k/yr+ Annual Incentive Plan + Long Term Incentive Plan
Expert
Bachelor's, Master's
United States
In PersonField-based across multiple states in the Northeast Region; up to 50% domestic travel, including overnight and some weekend travel.
Growth & MarketingMarketing Generalist & Management

About the job

Requirements
  • A bachelor's degree is required; an advanced degree is preferred.
  • A minimum of 10 years of experience in the pharmaceutical or healthcare field is required.
  • KOL engagement experience is strongly preferred.
  • Marketing experience is preferred.
  • Alzheimer's disease therapeutic-area experience is preferred.
  • Demonstrated leadership skills are required.
  • Demonstrated analytical and problem-solving skills are required.
  • Experience developing and implementing brand plans is required.
  • Strong communication and presentation skills are required.
  • Understanding of legal and regulatory issues affecting pharmaceutical product marketing, as well as the dynamics of the U.S. healthcare environment, is required.
  • The candidate must be a self-starter with strong clinical acumen, a solutions-oriented approach, and the ability to function autonomously.
  • The candidate must have an open, collaborative nature and the ability to rapidly integrate and motivate cross-functional team members and stakeholders.
  • The candidate must have high learning agility and be able to thrive in a rapidly evolving, complex, fast-paced environment.
  • Excellent verbal, written, and interpersonal skills, as well as emotional intelligence, are required.
  • In-depth knowledge of integrated health systems operations within the current market environment is required.
  • The candidate must demonstrate the ability to establish and maintain strong business relationships.
  • The candidate must be committed to patient-centricity, innovation, inclusion, and compliance.
  • The candidate must successfully complete all company training programs and customer-mandated and vendor credentialing requirements.
  • The candidate must be able to operate a motor vehicle legally, safely, and successfully and must have a valid driver's license.
  • Applicants must be able to engage in person with healthcare professionals and other third parties at their offices, institutions, and other appropriate locations on a regular basis; third-party credentialing or entry requirements may include vaccination attestations or proof, with reasonable accommodation available for qualifying medical or religious reasons.
Responsibilities
  • Develop and service targeted key accounts and establish and maintain preferred vendor or product status for accounts.
  • Study marketing information on retail and wholesale buying centers, chain store locations, health plans, group purchasing organizations, and insurance companies to identify additional sales needs.
  • Contact national accounts and deliver pre-planned sales presentations.
  • Assist in developing presentation packages, pricing structures, and new products.
  • Promote products to new and established national accounts to achieve sales objectives and increase market penetration.
  • Assist clients in evaluating the economic potential of their businesses.
  • Communicate marketing information to the field sales force to finalize sales.
  • Lead and execute regional and local engagement with existing and emerging key opinion leaders, advocacy groups, and professional societies to develop and implement Alzheimer's disease education that simplifies the patient journey from diagnosis through treatment and monitoring.
  • Identify emerging opinion leaders and engage key opinion leaders to support speaker bureau activities; assess speaker programs for meaningfulness, effectiveness, educational value, and compliance with company policies.
  • Engage national, regional, local, and emerging thought leaders, face-to-face where possible, to identify and seek insights on best practices that can simplify the patient journey.
  • Identify and ensure product, disease-state, and compliance training for promotional speakers and related speaker-program activities.
  • Collaborate with the Promotional Program Manager on speaker usage and issues.
  • Provide feedback on nominating new speakers when applicable.
  • Coordinate or facilitate new-product and annual compliance training.
  • Work with the Marketing Team on annual speaker recontracting.
  • Update and track key opinion leader engagements using the Veeva/Vector KOL management platform.
  • Collaborate with other field teams to support local and account-level engagement with national, emerging, and regional thought leaders.
  • Coordinate with the field sales team, brand leads, and speaker-program vendor on speaker availability and utilization.
  • Ensure appropriate use of speaker programs within allocated regional budgets.
  • Gather and communicate field feedback to the brand team about promotional programming.
  • Identify potential opportunities for institutional group training.
  • Identify, assess, and appropriately engage regional advocacy groups and local or regional professional societies in collaboration with Corporate.
  • Work with advocacy groups to develop and implement above-brand Alzheimer's disease education that simplifies the patient journey from diagnosis through patient monitoring.
  • Serve as a central point for field engagement with regional and local advocacy groups and professional societies.
  • Synthesize learnings, translate them into key insights and best practices, and regularly present those insights to marketing and sales leadership to inform brand strategy, messaging, educational initiatives, and promotional programs.
  • Monitor key opinion leaders' communications through publications, congresses, podium presentations, and one-to-one interactions.
  • Stay current on data readouts consistent with FDA-approved labeling, medical congress meeting outputs, and podium and symposia presentations.
  • Identify best practices to simplify the patient journey.
  • Engage with key opinion leaders affiliated with key regional health systems to understand the patient journey.
  • Travel domestically, including overnight trips and some weekends, for meetings with key opinion leaders, advocacy groups, professional societies, and conferences; the role involves up to 50% domestic travel.
Desired Qualifications
  • An advanced degree is preferred.
  • KOL engagement experience is strongly preferred.
  • Marketing experience is preferred.
  • Alzheimer's disease therapeutic-area experience is preferred.

About the company

E

Eisai

View
Website

Eisai is a Japanese research-based pharmaceutical company that discovers, develops, and markets prescription medicines under its "human health care (hhc)" concept. Its portfolio concentrates on neurology and oncology, including LEQEMBI (lecanemab), an anti-amyloid treatment for Alzheimer's disease now offered in intravenous and subcutaneous forms; lemborexant for insomnia; and the anticancer agent Halaven, developed through worldwide R&D and open-innovation partnerships. The company also runs a global health program that supplies medicines to more than 30 countries, having distributed billions of tablets to help eliminate neglected tropical diseases such as lymphatic filariasis. What sets Eisai apart is this hhc concept, which frames access and affordability—not only innovation—as central to its mission. The goal is to empower people to realize their fullest life by advancing treatments for conditions such as dementia and cancer.

Company Size

N/A

Company Stage

N/A

Total Funding

N/A

Headquarters

N/A

Founded

N/A

Simplify Jobs

Simplify's Take

What believers are saying

  • Leqembi Q1 fiscal 2026 sales hit 293 billion yen, up 27%.
  • Japan approved LEQEMBI Pen on September 16, 2026, expanding home administration.
  • Eurofarma will commercialize DAYVIGO in Brazil, extending Eisai's CNS reach.

What critics are saying

  • LEQEMBI faces ARIA, hemorrhage, and hypersensitivity risks that limit uptake and trigger monitoring.
  • FDA delayed IQLIK review once; future label changes can slow adoption.
  • Alzheimer's revenue concentration makes a Leqembi setback existential for Eisai's growth story.

What makes Eisai unique

  • Eisai owns LEQEMBI global development, commercialization, and final decision-making authority.
  • LEQEMBI IQLIK launched August 2026, offering at-home initiation and maintenance dosing.
  • DAYVIGO and LENVIMA broaden Eisai beyond Alzheimer's into insomnia and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Holidays
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Wellness Program
  • Mental Health Support
  • Conference Attendance Budget

Company News

Business Wire
Sep 25th, 2026
FDA approves Welireg plus Lenvima for advanced renal cell carcinoma after PD-1/PD-L1 therapy

The US Food and Drug Administration has approved the combination of WELIREG (belzutifan) and LENVIMA (lenvatinib) for treating adult patients with advanced renal cell carcinoma with a clear cell component following prior PD-1 or PD-L1 inhibitor therapy. The approval is based on the Phase 3 LITESPARK-011 trial involving 747 patients. The combination reduced the risk of disease progression or death by 26% compared to cabozantinib, achieving a median progression-free survival of 14.6 months versus 10.6 months. The objective response rate was 53% compared to 40% for cabozantinib. However, the trial's other primary endpoint, overall survival, did not meet statistical significance. This marks the first approved HIF-2α inhibitor plus tyrosine kinase inhibitor combination for this patient population. Merck and Eisai jointly announced the approval.

Healthcare Industry Today
Sep 16th, 2026
LEQEMBI(R) Pen (subcutaneous formulation of LEQEMBI(R) approved in Japan for the treatment of early Alzheimer's Disease.

LEQEMBI(R) Pen (subcutaneous formulation of LEQEMBI(R) approved in Japan for the treatment of early Alzheimer's Disease. The first and only anti-amyloid treatment in Japan that enable at-home administration for Alzheimer's Disease, a progressive disease. TOKYO and CAMBRIDGE, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that "LEQEMBI(R) Pen", the subcutaneous (SC) formulation of the anti-amyloid beta (Aβ) protofibril antibody "LEQEMBI(R)" (brand name, generic name: lecanemab) has been approved in Japan as a new route of administration. LEQEMBI Pen is an autoinjector formulation that enables administration by a care partner or patient self-administration, with two pens (totaling 500 mg) administered once weekly. With this approval, LEQEMBI treatment now offers a new option of once-weekly SC administration at home*, in addition to intravenous (IV) administration every two weeks in a hospital setting. LEQEMBI Pen may reduce the time required for anti-amyloid therapy administration compared with IV infusions (approximate injection time of 15 seconds per injection). In addition, at-home administration may reduce the burden of clinic visits for patients and their care partners and provide greater flexibility in treatment, allowing patients to make treatment choices that better fit their lifestyles, including fewer constraints on going out and traveling. The improved convenience and flexibility of treatment with LEQEMBI is expected to lower barriers to initiating and continuing treatment with LEQEMBI. Furthermore, LEQEMBI Pen also has the potential to reduce healthcare resources associated with IV dosing, such as nurse monitoring, as well as maintaining infusion capacity. These features are expected to contribute to further streamlining the overall Alzheimer's disease (AD) treatment pathway. For amyloid-related imaging abnormalities (ARIA) monitoring, as with IV administration, brain magnetic resonance imaging (MRI) is performed prior to initiating treatment and at specified time points after treatment initiation. AD is a progressive, relentless disease with Aβ and tau as hallmarks that is caused by a continuous underlying neurotoxic process driven by protofibrils that begins before amyloid plaque accumulation and continues after plaque removal.[1,2,] [3] Only LEQEMBI fights AD in two ways - targeting both protofibrils and amyloid plaque. This marks the third country globally to approve LEQEMBI SC formulation. This approval is based on the integrated results of data and associated modeling and simulation from the 18-month core study of the Phase 3 Clarity AD study of LEQEMBI in patients with mild cognitive impairment (MCI) due to AD or mild AD dementia (collectively referred to as early AD), as well as multiple SC administration sub-studies in its subsequent long-term extension study (LTE). Once-weekly administration of SC formulation 500 mg demonstrated similar exposure to IV administration once every two weeks and supported the expectation that the SC formulation provides efficacy comparable to that of the IV formulation. The overall safety profile of SC administration was generally similar to that of IV administration, while systemic injection/infusion-related reactions were observed less frequently with SC administration (1.4%)** than with IV administration. Eisai serves as the lead for lecanemab's development and regulatory submissions globally, with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. * At-home, self-administration using LEQEMBI Pen will be possible after it is listed in the injectable drug list designated by the Minister of Health, Labour and Welfare that health insurance doctor can administer (or prescribe), following deliberation and approval by the Central Social Insurance Medical Council, in principle within 60 days after approval. In addition, the following points are stipulated to be observed when self-administering. * When initiating administration, treatment must be administered by a physician or under the direct supervision of a physician at a medical facility. * With regard to the applicability of self-administration, the appropriateness thereof shall be carefully considered, and only after providing thorough education and training, and confirming that the patient or family member/caregiver understands the risks associated with administration of this drug and how to respond to them, and that the patient or family member/caregiver is able to reliably administer it themselves, shall self-administration be implemented under the management and guidance of a physician. ** Incidence in participants newly initiated on lecanemab treatment via SC administration, based on clinical data obtained from once-weekly subcutaneous administration of lecanemab 720 mg using vial formulations. | Eisai Co., Ltd. Public Relations Department TEL: +81 (0)3-3817-5120 Eisai Europe, Ltd. EMEA Communications Department +44 (0) 7760 619251 [email protected] Eisai Inc. (U.S.) Libby Holman +1-201-753-1945 [email protected] | Biogen Inc. Madeleine Shin +1-781-464-3260 [email protected] | | INVESTOR CONTACTS | / | | Eisai Co., Ltd. Investor Relations Department TEL: +81 (0) 3-3817-5122 | Biogen Inc. Tim Power + 1-781-464-2442 [email protected] | | / | / | Notes to Editors References * Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z * Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. * Hampel H, Hardy J, Blennow K, et al. The amyloid pathway in Alzheimer's disease. Mol Psychiatry. 2021;26(10):5481-5503. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Healthcare Industry Today do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

PR Newswire
Aug 24th, 2026
Leqembi Iqlik(R) for initiation treatment launched in the US.

Leqembi Iqlik(R) for initiation treatment launched in the US. Aug 24, 2026, 08:39 ET STOCKHOLM, Aug. 24, 2026 /PRNewswire/ - BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced that lecanemab-irmb subcutaneous injection (US brand name: Leqembi Iqlik(R), which was approved by the FDA on July 13, now is available in the US for initiation therapy for early Alzheimer's disease[1]. Leqembi Iqlik is the first-of-its-kind anti-amyloid treatment that offers at-home dosing for initiation and maintenance (approved in the US). Leqembi Iqlik is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) infusion from the start of treatment. For initiation, the approved regimen is 500 mg once weekly, delivered as two 250 mg injections, each administered in approximately 15 seconds. Expanding convenience and flexibility in Alzheimer's care The availability of Leqembi Iqlik for both initiation and maintenance therapy in the US offers patients and carers greater convenience and flexibility throughout the treatment journey. At-home administration reduces the need for IV infusions and clinic visits, making treatment easier to integrate into daily life. Leqembi Iqlik may also help reduce healthcare resource utilization associated with IV administration. As with intravenous treatment, MRI monitoring for ARIA is required before treatment initiation and at specified time points thereafter. The information was released for public disclosure, through the agency of the contact person below, on August 24, 2026, at 2:05 pm CEST. For further information, please contact: Oskar Bosson, Chief Investor Relations & Communications Officer E-mail: [email protected] Telephone: +46 704 107 180 Jenny Ljunggren, External Communications and Investor Relations Manager E-mail: [email protected] Telephone: +46 76 013 86 08 About Leqembi(R)(lecanemab) Leqembi is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Leqembi is approved in 53 countries and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks is approved in 8 countries, including the United Kingdom, China, the US and Japan, and applications have been filed in 12 countries and regions. In the US, Leqembi Iqlik(R) is approved for subcutaneous dosing with an autoinjector as a starting dose and maintenance treatment of early Alzheimer's disease. In November 2025, a new drug application for subcutaneous formulation of Leqembi was submitted in Japan. In December 2025, Leqembi was included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security Administration (NHSA) of China. In January 2026, the Biologics License Application for subcutaneous formulation of Leqembi was accepted in China and in February, the application was designated for priority review. Since July 2020, Eisai's Phase 3 clinical study (AHEAD 3-45) with lecanemab in individuals with preclinical Alzheimer's disease meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. The study was fully recruited in October 2024. AHEAD 3-45 is a four-year study conducted as a public-private partnership between Eisai, Biogen and the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in Alzheimer's disease and related dementias in the US, funded by the National Institute on Aging, part of the National Institutes of Health. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited Alzheimer's disease (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy. About the collaboration between BioArctic and Eisai Since 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the Development and Commercialization agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody lecanemab back-up for Alzheimer's disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. BioArctic has the right to commercialize lecanemab in the Nordic region and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer's disease and is entitled to payments in connection with sales milestones as well as royalties on global sales. About BioArctic AB BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi(R)(lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter(TM) technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com. [[1]] Mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease, is collectively referred to as early Alzheimer's disease. The following files are available for download: | https://mb.cision.com/Main/9978/4387047/4230386.pdf | Leqembi Iqlik(R) for initiation treatment launched in the US |. SOURCE BioArctic

Eurofarma
Aug 18th, 2026
Eurofarma announces strategic alliance with Eisai for the commercialization of DAYVIGO(R) in Brazil.

Eurofarma announces strategic alliance with Eisai for the commercialization of DAYVIGO(R) in Brazil. Innovative medicine with a novel mechanism of action to enter the Brazilian market this year marking a new era in insomnia treatment Published in: August 17, 2026 and updated in: August 18, 2026 * To share Listen to the text São Paulo, August 17th de 2026 - Eurofarma and Eisai Laboratórios Ltda. ("Eisai") today announced a strategic alliance for the commercialization of DAYVIGO(R)(lemborexant), an innovative medicine indicated for the treatment of insomnia in adults and the first dual orexin receptor antagonist (DORA) approved in Brazil. The medicine has demonstrated consistent efficacy in sleep onset and maintenance across objective and patient-reported measures, with robust evidence of promoting a transition to sleep that more closely resembles the natural sleep pattern, with no evidence of risk of dependence.[1-3] Under the terms of the agreement, Eurofarma will be responsible for the commercialization, promotion, and distribution of DAYVIGO(R) throughout the country. Eisai will remain responsible for the product's marketing authorization and defining the brand's overall strategy in Brazil. The collaboration combines Eisai's global expertise in sleep medicine and central nervous system disorders with Eurofarma's extensive commercial reach, strong local market presence, and expertise in the central nervous system area, helping expand access to innovative treatment options for people living with insomnia. Insomnia is characterized by difficulty falling asleep, staying asleep, or both despite an adequate opportunity to sleep. When it occurs at least three times per week for a minimum period of one months, it may lead to fatigue, difficulty concentrating, and irritability[4,5]. The prevalence of insomnia disorder among adults in Brazil is estimated at approximately 15%[6], representing around 24 million adults living with the condition. Currently, the most commonly prescribed medications for insomnia in the country act directly by inducing drowsiness, and there is growing demand for new therapeutic options. "At Eurofarma, we continuously seek to identify and provide innovations capable of transforming people's lives. This partnership reinforces our strategy of connecting patients with differentiated, high-impact therapies, helping to raise the standard of care in areas with significant unmet medical needs", said João Siffert, Vice President of Innovation, Eurofarma. "This collaboration represents more than a commercial agreement; it reflects a shared commitment to addressing unmet medical needs in Brazil. By combining Eisai's scientific leadership in neuroscience with Eurofarma's extensive market expertise, we are expanding access to innovative therapies for people living with insomnia. Together, we are creating value for patients, healthcare professionals, and society", said Priscila Cavalcante, Commercial Director at Eisai. About DAYVIGO(R)(Lemborexant) DAYVIGO(R), an orexin receptor antagonist, is Eisai's in-house discovered and developed small molecule and has been approved by the Brazilian Health Regulatory Agency (Anvisa) for the treatment of insomnia in adults characterized by difficulty initiating and/or maintaining sleep. It is a small molecule that inhibits orexin neurotransmission by competitively binding to both orexin receptor subtypes (orexin receptor 1 and orexin receptor 2)[8]. Its rapid association with and dissociation from orexin receptors may help improve both sleep onset and sleep maintenance[9]. The product has already been approved for the treatment of insomnia in more than 28 countries, including Japan, the United States, Canada, Australia, and several countries across Asia[10]. In randomized studies using both objective and subjective assessments, individuals treated with lemborexant demonstrated improvements in sleep parameters compared with placebo, including reduced sleep onset latency, increased sleep duration, and improved sleep efficiency. Efficacy and tolerability have also been shown to be maintained over 12 months of treatment. Furthermore, no evidence of rebound insomnia or withdrawal symptoms was observed following treatment discontinuation[3,6,11,12]. Studies conducted in both adults and older adults have also shown that lemborexant is not associated with clinically relevant residual morning effects, such as impaired postural stability upon awakening or reduced driving performance the next morning. Additionally, the medicine did not impair the ability to awaken in response to auditory stimuli[11-13]. The arrival of DAYVIGO(R) in the Brazilian market symbolizes a paradigm shift in a therapeutic area that has remained relatively stable for decades, representing one of the most significant recent innovations in sleep medicine. Referências 1. DRAGER, Luciano Ferreira et al. Consenso de diagnóstico e tratamento da insônia em adultos 2023. São Paulo: Segmento Farma Editores, 2023. Available at: Brazilian Insomnia Consensus. Accessed: January 20, 2026. 2. Kärppä M, Yardley J, Pinner K, Filippov G, Zammit G, Moline M, Perdomo C, Inoue Y, Ishikawa K, Kubota N. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep. 2020 Sep 14;43(9):zsaa123. 3. Rosenberg R, Murphy P, Zammit G, Mayleben D, Kumar D, Dhadda S, Filippov G, LoPresti A, Moline M. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial. JAMA Network Open. 2019 Dec 2;2(12):e1918254. 4. Ferrie JE, et al. Sleep epidemiology: a rapidly growing field. International Journal of Epidemiology. 2011;40(6):1431-1437. 5. Roth T. Insomnia: definition, prevalence, etiology and consequences. Journal of Clinical Sleep Medicine. 2007;3(5 Suppl):S7-S10. 6. Castro LS, Poyares D, et al. Objective prevalence of insomnia in the São Paulo, Brazil epidemiologic sleep study. Annals of Neurology. 2013;74(4):537-546. 7. Internal estimate. 8. Muehlan C, et al. The orexin story and orexin receptor antagonists for the treatment of insomnia. Journal of Sleep Research. 2023 Dec;32(6):e13902. 9. Beuckmann CT, et al. In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist. Journal of Pharmacology and Experimental Therapeutics. 2017 Aug;362(2):287-295. 10. Eisai Global. 2025. Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R)(Lemborexant) in China. Available at: Eisai News Release. Last accessed: July 2026. 11. Murphy P, Kumar D, Zammit G, Rosenberg R, Moline M. Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening. Journal of Clinical Sleep Medicine. 2020 May 15;16(5):765-773. 12. Gotfried MH, Auerbach SH, Dang-Vu TT, Mishima K, Kumar D, Moline M, Malhotra M. Efficacy and safety of insomnia treatment with lemborexant in older adults: analyses from three clinical trials. Drugs & Aging. 2024 Sep;41(9):741-752. 13. Vermeeren A, Jongen S, Murphy P, Moline M, Filippov G, Pinner K, Perdomo C, Landry I, Majid O, Van Oers ACM, Van Leeuwen CJ, Ramaekers JG, Vuurman EFPM. On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers. Sleep. 2019 Apr 1;42(4):zsy260. Erratum in: Sleep. 2020 Jul 13;43(7):zsaa068. About Eurofarma Founded in 1972, Eurofarma operates in the healthcare sector through the production and commercialization of products and services aimed at improving people's quality of life. Focused on generating shared value, the company operates across the main pharmaceutical segments, including prescription medicines, generics, hospital products, oncology, OTC medicines, personal care, and animal health, in addition to providing third-party manufacturing services. With broad therapeutic coverage, its portfolio includes more than 4,000 SKUs, serving virtually all medical specialties. The leader in prescription medicines in Brazil and the second-largest player in generics in the country, Eurofarma is present in 24 countries, with full coverage across Latin America and regional leadership in the retail market. The company also maintains operations in the United States and Africa, employs more than 13,000 people, and operated 10 manufacturing plants, producing 630 million units in 2025. In the same year, Eurofarma invested more than BRL 700 million in innovation projects and achieved net revenue exceeding BRL 12 billion. About Eisai Laboratórios Ltda. Founded in 2011 and headquartered in São Paulo, Eisai Laboratórios Ltda. is the Brazilian subsidiary of Eisai Co., Ltd., a global pharmaceutical company founded in Japan in 1941. The company is dedicated to improving the lives of patients and their families in Brazil by delivering innovative medicines that address significant unmet medical needs. Eisai's corporate concept is to give first thought to patients and people in the daily living domain, known as its human health care (hhc) concept. Guided by this philosophy, Eisai strives to create and deliver innovative medicines that address unmet medical needs, particularly in the strategic areas of Neurology and Oncology. Through its global network of research and development facilities, manufacturing sites and marketing subsidiaries, Eisai is committed to increasing the benefits that healthcare provides, relieving anxiety over health, and reducing health disparities around the world. Media Contact Eurofarma G&A Relações Públicas Iza França - 11 97644-4496 - [email protected] Guilherme Gaspar - 11 98285-6000 - [email protected] Murillo Israel - [email protected]

Eisai
Aug 18th, 2026
WashU Medicine honors CEO Haruo Naito and Eisai for longstanding contributions to Alzheimer's disease research and healthcare.

WashU Medicine honors CEO Haruo Naito and Eisai for longstanding contributions to Alzheimer's disease research and healthcare. August 18, 2026 Eisai Co., Ltd. (Headquarters: Tokyo, "Eisai") announced today that Washington University School of Medicine in St. Louis ("WashU Medicine") held a ceremony unveiling a plaque honoring the longstanding contributions and achievements of CEO Haruo Naito and Eisai in healthcare, including in the field of Alzheimer's disease (AD). The plaque, commemorating these achievements, will be permanently displayed on a wall in the lobby of the Jeffrey T. Fort Neuroscience Research Building (NRB). CEO Haruo Naito and Eisai were recognized for their long-term and significant contributions to WashU Medicine and the Knight Family Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), as well as for the profound impact CEO Naito's leadership and vision have had on patients, families and researchers around the world. Eisai and WashU Medicine have been collaborating in research on neurodegenerative diseases, including dementia and Parkinson's disease. In particular, in the AD field, the Phase II/III Tau NexGen Study conducted by the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by the University's School of Medicine, is exploring the safety, tolerability, biomarkers and cognitive efficacy of Eisai's anti-MTBR (microtubule binding region) tau antibody etalanetug (E2814) for the treatment of dominantly inherited Alzheimer's disease (DIAD). In this study, the anti-amyloid beta (Aβ) protofibril antibody lecanemab was selected as the backbone anti-amyloid therapy. The collaboration between WashU Medicine neuroscience researchers and Eisai reinforces a shared mission of advancing human healthcare, which accelerates turning discoveries from medical research into solutions for patients, improving care for families today while working toward a future free of neurodegenerative disease. Media contacts: Public Relations Department, Eisai Co., Ltd.